Send the following on WhatsApp
Continue to Chathttps://www.marketscreener.com/quote/stock/OSE-IMMUNOTHERAPEUTICS-21120309/news/Boehringer-Ingelheim-and-OSE-Immunotherapeutics-Present-Phase-1-Results-with-First-in-Class-SIRPa-In-36452628/?utm_source=whatsapp&utm_medium=social&utm_campaign=share